| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
109,640,000 |
| Market
Cap: |
76.20(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.7 - $2.23 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.9 |
| Insider 6 Months : 4.9 |
| Insider 3/6 Months : 10 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Viaskin™. Co.'s therapeutic approach is based on epicutaneous immunotherapy, or EPIT™, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin™. Co.'s lead product candidate, Viaskin™ Peanut, has completed a global Phase III program for the treatment of peanut-allergic patients four to 11 years of age. Co.'s second product candidate, Viaskin™ Milk, is in development for the treatment of cow's milk protein allergy children two to 17 years of age.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
18,919 |
18,919 |
45,919 |
45,919 |
| Total Buy Value |
$15,812 |
$15,812 |
$58,352 |
$58,352 |
| Total People Bought |
2 |
2 |
4 |
4 |
| Total Buy Transactions |
2 |
2 |
4 |
4 |
| Total Shares Sold |
0 |
2,245 |
2,714 |
4,506 |
| Total Sell Value |
$0 |
$3,906 |
$5,566 |
$10,727 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
2 |
3 |
| End Date |
2024-01-14 |
2023-10-13 |
2023-04-14 |
2022-04-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tasse Daniel |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-03-08 |
4 |
B |
$0.83 |
$14,188 |
D/D |
17,094 |
17,094 |
0.01 |
-19% |
|
| Ndu Adora |
|
– • – |
2024-02-06 |
4 |
B |
$0.89 |
$1,624 |
D/D |
1,825 |
1,825 |
0.01 |
-22% |
|
| Mohideen Pharis |
Chief Medical Officer |
• – – |
2023-11-22 |
4 |
S |
$1.74 |
$3,906 |
D/D |
(2,245) |
82,194 |
|
13% |
|
| Mohideen Pharis |
Chief Medical Officer |
• – – |
2023-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
84,439 |
|
- |
|
| Boucinha Virginie |
Chief Financial Officer |
• – – |
2023-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
19,000 |
19,000 |
|
- |
|
| Morris Timothy E |
Director |
– • – |
2023-08-25 |
4 |
B |
$1.52 |
$18,240 |
D/D |
12,000 |
12,000 |
2.39 |
-39% |
|
| Soland Daniel B |
Director |
– • – |
2023-08-01 |
4 |
B |
$1.62 |
$24,300 |
D/D |
15,000 |
20,000 |
2.39 |
-51% |
|
| Mohideen Pharis |
Chief Medical Officer |
• – – |
2023-05-24 |
4 |
S |
$3.54 |
$1,660 |
D/D |
(469) |
49,439 |
|
34% |
|
| Mohideen Pharis |
Chief Medical Officer |
• – – |
2022-11-24 |
4 |
S |
$2.88 |
$5,161 |
D/D |
(1,792) |
49,908 |
|
-26% |
|
| Robitaille Sebastien |
Chief Financial Officer |
• – – |
2022-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
36,500 |
|
- |
|
| Mohideen Pharis |
Chief Medical Officer |
• – – |
2022-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
51,700 |
|
- |
|
| Mohideen Pharis |
Chief Medical Officer |
• – – |
2022-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
34,200 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2022-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
11,875,000 |
14,575,984 |
|
- |
|
| Mohideen Pharis |
Chief Medical Officer |
• – – |
2021-11-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,700 |
24,200 |
|
- |
|
| De Rosen Michel |
Director |
– • – |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,570 |
|
118% |
|
| Bjerke Torbjorn |
Director |
– • – |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,925 |
|
118% |
|
| Monges Viviane |
Director |
– • – |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
600 |
|
118% |
|
| Soland Daniel B |
Director |
– • – |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
118% |
|
| Robitaille Sebastien |
Chief Financial OfficerOfficer |
• – – |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,500 |
|
118% |
|
| Baker Julian |
Director |
– • • |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,286,038 |
|
118% |
|
| Mohideen Pharis |
Chief Medical OfficerOfficer |
• – – |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,500 |
|
118% |
|
21 Records found
|
1
|
Page 1 of 1 |
|
|
